Johnson and Johnson ( J&J) Medical Devices Companies, through its division Apsis, has acquired French surgical technologies developer Orthotaxy for an undisclosed amount.
The deal includes a robotic-assisted surgery solution currently being developed by Orthotaxy for both total and partial knee replacement.
J&J intends to advance this solution as a cost-effective, time-efficient and easy-to-use option for a wide variety of orthopaedic surgery procedures and care settings.
The firm will primarily devise its complete orthopaedic solution based on the Orthotaxy’s technology. The new solution will be designed to leverage enabling technologies to personalise and optimise surgical procedures.
J&J’s orthopaedics unit DePuy Synthes group chairman Ciro Rӧmer said: “Our goal is to bring to market a robotic-assisted surgery technology that is an integral part of a comprehensive orthopaedics platform, delivering value to patients, physicians and healthcare providers across the episode of care.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
“The team at Orthotaxy has significant expertise and passion in developing this platform, and we aspire to bring to market a differentiated technology that helps improve clinical outcomes and increases patient satisfaction.”
J&J believes that the latest deal is in line with its goal to develop a comprehensive digital surgery platform for better patient outcomes and standard of care.
The firm plans to further develop digital technology solutions that will deliver transformative care.
In addition to products for general surgery, J&J’s medical device portfolio includes orthopaedic and cardiovascular disease solutions.